AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 221 min read$ROIV

Sukhatme Mayukh sold $12.4M of ROIV

Sukhatme Mayukh (President & CIO) sold 335,174 shares of Roivant Sciences Ltd. (ROIV) at an average of $36.88 ($36.48–$37.30, $12.36M total) across 3 trades over 2026-08-19 to 2026-08-21.

Original reporting
SEC EDGAR · Sukhatme Mayukh
Published Aug 22, 2026, 1:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 22, 2026, 1:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ROIV
Bearish
medium confidence
Mentioned
$ROIV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ROIVBearishLow
01

Why it matters

The sale reduces insider ownership to 18.6M shares, indicating a 1.8% stake after the transaction.

02

Market read

First public disclosure of a significant insider sale; may influence short-term trading sentiment.

03

What to watch

Potential upcoming financing or strategic moves not disclosed.

Relevance 7/10Novelty 7/10Timing: filed 2026-08-21

Background

SEC Form 4 filing discloses insider transaction for Roivant Sciences Ltd.

Company-level read

Ticker impact

$ROIVBearishMedium confidence
Context

Form 4 shows President & CIO sold 335,174 shares for $12.36M, reducing his stake.

Expected impact

Possible modest price dip in near term.

Evidence & confidence

Insider sale of $12M by a top executive is material but not unusual; market may react cautiously.

Market effects

Sector

Minimal impact on biotech sector; insider activity is company-specific.

Regional

Limited to US-listed biotech investors.

Global

Low global relevance.

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not necessarily reflect company outlook.

Key entities

  • Officer
    Sukhatme Mayukh

    President & CIO of Roivant Sciences Ltd.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ROIV insider trading history →

Related articles

SEP 13
$ROIVHighAI 9/10

Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story

Roivant Sciences (ROIV) shares rose 18% after reporting positive Phase 2 results for Mosliciguat, a pulmonary hypertension treatment. The drug showed a 56.3% reduction in pulmonary vascular resistance and a 35.2-meter improvement in six-minute walk distance. Analysts suggest potential $10B annual sales. Success in Phase 3 trials is critical for commercialization and long-term growth.

yahoo.com2 min
SEP 8
$BJDXMedAI 8/10

5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

rttnews.com3 min